Serplulimab, a novel anti-pd-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase ii trial

HIGHLIGHTS

• who: Shukui Qin from the on Behalf of CR UK have published the paper: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial, in the Journal: (JOURNAL) of 29/01/2022
• what: The main reason for exclusion was not meeting the eligibility criteria. A consistently favourable antitumour activity for serplulimab was demonstrated by IRRC assessments per iRECIST and by investigator assessments per RECIST v1.1 or iRECIST (Supplementary Tables S1 and S2).
• how: In this study outcomes were . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.